Recent advances in personalized medicine have enabled the treatment of NTRK fusion-positive tumors with targeted therapies, regardless of the cancer type or its origin. This approach, known as tumor-agnostic treatment, has received accelerated approval from the US FDA for repotrectinib in patients aged 12 and older with locally advanced or metastatic tumors or in cases where surgical resection may lead to severe morbidity. Clinical trial The efficacy of repotrectinib was evaluated in a multicenter, single-arm, open-label trial, named TRIDENT-1 (NCT03093116), involving 88 adult patients with locally advanced or metastatic NTRK gene fusion-positive solid tumors.
The study included two cohorts: 1. Patients who had previously received a TRK tyrosine kinase inhibitor (TKI) (n=48) 2. TKI-naïve patients (n=40) At baseline, all patients were assessed for central nervous system…
